ATIC

30/04/2026

In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) is currently considering an application to fund Teplizumab (TZield) for people at risk of developing type 1 diabetes—specifically those with two or more autoantibodies.
For individuals who respond to this medication, studies have shown it can delay the onset of insulin-dependent type 1 diabetes by approximately two years. This has the potential to make a meaningful difference for individuals and families navigating this journey.
PBAC is now seeking input from people with lived experience of type 1 diabetes, their loved ones, healthcare professionals, and members of the broader community.
If you’d like to share your thoughts on Teplizumab and the impact it could have for the type 1 diabetes community in Australia, you can find details on how to provide feedback in the post below.
Your voice can help inform this important decision.

28/04/2026

We were excited to see the latest clinical trial results from SAB BIO presented at the Immunology of Diabetes Society Congress in Brisbane last week.
The SAB BIO team shared results from 4 people living with type 1 diabetes who took part in a trial of their medication SAB-142 that was run by ATIC here in Australia. These were the first four people with T1D to receive this medication.
The results showed that the 4 adults who received this medication were able to preserve their C-peptide levels. This matters because C-peptide helps us understand how much insulin the body is still making on its own. They also had improved time in range in their CGM data. You can read the full press release from the company here: https://ir.sab.bio/news-releases/news-release-details/sab-bio-presents-additional-clinical-and-mechanistic-data-sab
While these are very early results, they represent an encouraging step forward in developing potential new treatments for people living with type 1 diabetes.
ATIC is currently recruiting participants in Victoria, Queensland, New South Wales and New Zealand for a larger trial of this medication, the SAFEGUARD Study.
If you or someone you know has been diagnosed with T1D in the last 100 days, please see details of this study below or visit our website: https://atic.svi.edu.au/clinical-trials/clinical-trials/

27/04/2026

We were excited to see the latest clinical trial results from Mozart Therapeutics, Inc. presented at the Immunology of Diabetes Society Congress in Brisbane last week.
The Mozart team shared early results from 5 people living with type 1 diabetes who have taken part in the MTX-101-101 trial so far, currently being run by ATIC here in Australia.
From this very early data analysis, it appears that adults who received this medication were able to maintain or even increase their C-peptide levels for up to 20 weeks after treatment. This matters because C-peptide helps us understand how much insulin the body is still making on its own.
While these are early results, they represent an encouraging step forward in developing this potential new treatment for people living with type 1 diabetes.
ATIC is urgently seeking people with type 1 diabetes to help us complete this trial. The trial is currently being run in Victoria, with Queensland sites coming soon. Please see details below or visit the ATIC website https://atic.svi.edu.au/clinical-trials/clinical-trials/

24/04/2026

24/04/2026

ATIC are very proud and offer our heartfelt congratulations to our leader Thomas Kay on receiving the Breakthrough T1D Luminary Award for his dedication to type 1 diabetes at the Immunology of Diabetes Society Congress dinner last night. A lovely recognition of his immense contribution to the field. Congratulations!

23/04/2026

The ATIC team is having a great week at a diabetes and immunology conference in Brisbane.
We’ve been learning about the latest research into the immune system and diabetes, and presenting our own work with experts from around the world.
It’s also been really valuable to meet with our collaborators in person and talk about future clinical trials in Australia that aim to improve treatment options for people with, and at risk of type 1 diabetes. .

22/04/2026

ATIC is recruiting participants for the ASITI-201 Study being run at the Princess Alexandra Hospital, Brisbane.

This study is looking for people who are:
- Aged between 18 and 55 years
- Diagnosed with type 1 diabetes within the last 5 years
- Able to attend study visits at the Princess Alexandra Hospital, Brisbane.

For more information visit: www.atic.svi.edu.au/clinical-trials/ or contact the ASITI-201 Study research team: fi.thomasresearch@uq.edu.au

21/04/2026

ATIC are thrilled to support the next generation of clinician-researchers to attend the Immunology of Diabetes Society Congress in Brisbane this week. This group represent ATIC clinical sites from across the country. With great minds like these, the future of type 1 diabetes research in Australia is very bright!

19/04/2026

How wonderful it is to have an international diabetes conference held right here in Australia!
ATIC researchers are this week headed to the Immunology of Diabetes Society Congress and Australian Islet Study Group Meeting in Brisbane to present our work and learn from others. We look forward to sharing our learnings with you across the week.

17/04/2026

Did you know that ATIC stands for Australasian Type 1 diabetes Immunotherapy Collaborative? So where does immunotherapy fit in the type 1 diabetes puzzle and why are the team so passionate about immunotherapy research in type 1 diabetes? This short animation answers these questions!
Thank-you to Diabetes UK for use of the animation and to our ATIC community engagement panel who guided its development to ensure it reflects the experiences and voices of our local type 1 diabetes community.

AcknowledgementThis video resource was developed by the Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) with leadership and input from the AT...

15/04/2026

Are you interested in screening for type 1 diabetes?
In Australia, there is no better time - screening has been shown to reduce the risk of diabetes ketoacidosis (DKA) at diagnosis and also may open the door to participate in clinical trials that hopeto delay or stop the progression to insulin treatment.
Screening is available to people in Australia who have a family member with type 1 diabetes. It is free, easy and can be completed with a finger prick kit in the comfort of your home.
Find out more at www.type1screen.org

13/04/2026

We talk a lot about clinical trials here at ATIC. So what are clinical trials and how do they help? The Australian Clinical Trials Alliance have put together this fantastic clip explaining clinical trials - we thought it was too fantastic not to share! We hope that you enjoy it.

This resource is from the Consumer Involvement and Engagement Toolkit at www.involvementtoolkit.clinicaltrialsalliance.org.au